Connect with us

Health

Regeneron suspends COVID-19 antibody trial among sickest patients – Gulf News

Move follows recommendation from independent committee which assesses results

Published

on

post featured image

A Regeneron Pharmaceuticals scientist works in the company’s Infectious disease lab in New York state on an experimental coronavirus antibody drug.
Image Credit: Regeneron / via AP file
Washington: US biotech firm Regeneron on Friday said it was suspending enrollment for a study of its COVID-19 antibody treatment among the sickest patients who require high-flow oxygen or are on ventilators.
The move follows a recommendation from an independent data monitoring committee (IDMC) which assesses the…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending